Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen

Sim, Adrian Chong Nyi; Lin, Wen-Wei; Tan, Geok Kheng; Sim, Magenta S.T.; Chow, Vincent T. K.; Alonso, Sylvie

doi:10.1016/j.vaccine.2007.12.047

Cited by 44 publications

(29 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PRNT was carried out as described previously [36] with modifications. Briefly, mouse serum samples were heated at 56°C for 30 min to inactivate complement.…”

Section: Methodsmentioning

confidence: 99%

A Non Mouse-Adapted Dengue Virus Strain as a New Model of Severe Dengue Infection in AG129 Mice

et al. 2010

Self Cite

View full text Add to dashboard Cite

The spread of dengue (DEN) worldwide combined with an increased severity of the DEN-associated clinical outcomes have made this mosquito-borne virus of great global public health importance. Progress in understanding DEN pathogenesis and in developing effective treatments has been hampered by the lack of a suitable small animal model. Most of the DEN clinical isolates and cell culture-passaged DEN virus strains reported so far require either host adaptation, inoculation with a high dose and/or intravenous administration to elicit a virulent phenotype in mice which results, at best, in a productive infection with no, few, or irrelevant disease manifestations, and with mice dying within few days at the peak of viremia. Here we describe a non-mouse-adapted DEN2 virus strain (D2Y98P) that is highly infectious in AG129 mice (lacking interferon-α/β and -γ receptors) upon intraperitoneal administration. Infection with a high dose of D2Y98P induced cytokine storm, massive organ damage, and severe vascular leakage, leading to haemorrhage and rapid death of the animals at the peak of viremia. In contrast, very interestingly and uniquely, infection with a low dose of D2Y98P led to asymptomatic viral dissemination and replication in relevant organs, followed by non-paralytic death of the animals few days after virus clearance, similar to the disease kinetic in humans. Spleen damage, liver dysfunction and increased vascular permeability, but no haemorrhage, were observed in moribund animals, suggesting intact vascular integrity, a cardinal feature in DEN shock syndrome. Infection with D2Y98P thus offers the opportunity to further decipher some of the aspects of dengue pathogenesis and provides a new platform for drug and vaccine testing.

show abstract

“…PRNT was carried out as described previously [36] with modifications. Briefly, mouse serum samples were heated at 56°C for 30 min to inactivate complement.…”

Section: Methodsmentioning

confidence: 99%

A Non Mouse-Adapted Dengue Virus Strain as a New Model of Severe Dengue Infection in AG129 Mice

et al. 2010

Self Cite

View full text Add to dashboard Cite

show abstract

“…Their greatest advantage, however, is their ability to trigger mucosal and systemic immune responses against foreign microbial infections (Sim et al, 2008). Thus, many investigators are currently focused on the development of mucosal vaccines for oral administration.…”

Section: Discussionmentioning

confidence: 99%

Lactobacillus plantarum vaccine vector expressing hemagglutinin provides protection against H9N2 challenge infection

Shi

Yang

et al. 2016

Virus Research

View full text Add to dashboard Cite

“…However, when sera from individually immunized mice were examined only 3 out of 10 sera showed specific reactivity with VP7 [22]. Finally recent work has demonstrated that L. lactis expressing domain III of the major dengue virus envelope protein E (EDIII) may provide a successful vaccine platform when administered either orally or intranasally, although results varied between mouse strains used [23].…”

Section: Overview Of Vaccination Studies Utili-zing Engineered L Lacmentioning

confidence: 99%

Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins

Bahey-El-Din

Gahan²,

Griffin³

2010

CGT

View full text Add to dashboard Cite

The food-grade bacterium Lactococcus lactis has been extensively investigated during the last two decades as a delivery vector for therapeutic proteins, DNA and vaccine antigens. The bacterium represents a safe, genetically tractable vector capable of producing heterologous therapeutic proteins at mucosal sites. Here we review recent work in which recombinant L. lactis strains have been exploited as agents to treat inflammatory bowel disease, allergy and cancer. We also describe the ability of L. lactis to deliver proteins with adjuvant potential, vaccines and DNA and discuss the therapeutic possibilities of this approach.

show abstract

Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen

Cited by 44 publications

References 70 publications

A Non Mouse-Adapted Dengue Virus Strain as a New Model of Severe Dengue Infection in AG129 Mice

A Non Mouse-Adapted Dengue Virus Strain as a New Model of Severe Dengue Infection in AG129 Mice

Lactobacillus plantarum vaccine vector expressing hemagglutinin provides protection against H9N2 challenge infection

Lactococcus lactis as a Cell Factory for Delivery of Therapeutic Proteins

Contact Info

Product

Resources

About